CPT code 67221 identifies a specialized ophthalmic interventional procedure in which a provider infuses a photosensitive drug into the eye to treat a localized cancerous focus in the middle layer (uveal tract) and activates the agent using a laser. The code captures a targeted, eye-preserving treatment option for intraocular neoplasms and is relevant for ophthalmologists, oncology teams, and payers managing high-acuity ocular oncology services. Nationally, the procedure is significant because it represents a modality that can reduce the need for more invasive surgery and can impact utilization patterns in ambulatory surgical centers and hospital outpatient departments.

This publication covers coverage and reimbursement context for major payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find: benchmark descriptions of typical sites of service and service type; an explanation of clinical context and procedural intent; and a concise guide to where to find additional coding, billing, and coverage resources. Data not available in the input is noted where applicable. The piece is intended to inform clinical billing staff, coding professionals, and policy analysts about the clinical scope of CPT code 67221, payer relevance, and practical considerations for billing and site-of-service classification.